Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from CG Oncology, Inc. ( (CGON) ) is now available.
CG Oncology, Inc. presented an updated corporate presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025, highlighting the potential of their investigational drug, cretostimogene grenadenorepvec, in treating bladder cancer. The presentation emphasized promising clinical trial results, including high response rates and a favorable safety profile, positioning the company to capitalize on a multi-billion dollar market opportunity in non-muscle invasive bladder cancer (NMIBC).
The most recent analyst rating on (CGON) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc. benefits from strong technical momentum and promising trial results, which are significant positives. However, financial challenges and valuation concerns due to ongoing losses temper the overall score.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
CG Oncology, Inc. operates in the biotechnology industry, focusing on developing innovative cancer treatments. The company is primarily engaged in the research and development of cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy targeting bladder cancer.
Average Trading Volume: 840,566
Technical Sentiment Signal: Buy
Current Market Cap: $2.52B
See more data about CGON stock on TipRanks’ Stock Analysis page.